Sumitomo Mitsui DS Asset Management Company Ltd Has $2.88 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,969 shares of the company’s stock after purchasing an additional 306 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Moderna were worth $2,881,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. First Pacific Financial bought a new stake in Moderna during the third quarter worth $27,000. Arlington Trust Co LLC grew its holdings in Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC grew its holdings in Moderna by 54.1% during the third quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock worth $53,000 after buying an additional 180 shares in the last quarter. Archer Investment Corp grew its holdings in Moderna by 71.2% during the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock worth $55,000 after buying an additional 222 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its holdings in Moderna by 44.9% during the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock worth $58,000 after buying an additional 175 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the sale, the insider now owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Moderna news, insider Shannon Thyme Klinger sold 544 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the sale, the insider now owns 9,267 shares of the company’s stock, valued at approximately $917,896.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the sale, the director now directly owns 2,056,931 shares in the company, valued at approximately $212,645,526.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 109,954 shares of company stock valued at $11,533,976. Corporate insiders own 15.20% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on MRNA shares. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective for the company in a research note on Tuesday, January 2nd. Canaccord Genuity Group upped their price objective on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research note on Friday, February 23rd. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. HSBC restated a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Finally, William Blair restated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $126.49.

Moderna Stock Performance

Shares of MRNA opened at $107.89 on Wednesday. The stock’s 50-day simple moving average is $101.39 and its 200 day simple moving average is $93.53. The stock has a market capitalization of $41.31 billion, a price-to-earnings ratio of -8.69 and a beta of 1.62. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm’s quarterly revenue was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.61 EPS. Research analysts forecast that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.